Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 3, 2014, Pages 1372-1380

  Luyt, Charles Edouard ^a,b   Aubry, Alexandra ^a,b   Lu, Qin ^a,b   Micaelo, Maïté ^a,b   Bréchot, Nicolas ^a,b   Brossier, Florence ^a,b   Brisson, Hélène ^a,b   Rouby, Jean Jacques ^a,b   Trouillet, Jean Louis ^a,b   Combes, Alain ^a,b   Jarlier, Vincent ^a,b   Chastre, Jean ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; DORIPENEM; FOSFOMYCIN; IMIPENEM; MEROPENEM; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIUM ISOLATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MECHANICAL VENTILATOR; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIDRUG RESISTANCE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; PSEUDOMONADACEAE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; RECURRENCE RISK; RECURRENT INFECTION; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CARBAPENEMS; DISK DIFFUSION ANTIMICROBIAL TESTS; FEMALE; HUMANS; IMIPENEM; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; PSEUDOMONAS INFECTIONS; THIENAMYCINS;

EID: 84896831450     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02109-13     Document Type: Article

References (33)

1. Chastre J, Fagon JY. 2002. Ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 165:867-903. http://dx.doi.org/10.1164/ajrccm.165.7. 2105078. (Pubitemid 34774654)
2. Fujitani S, Sun HY, Yu VL, Weingarten JA. 2011. Pneumonia due to Pseudomonas aeruginosa. Part I. Epidemiology, clinical diagnosis, and source. Chest 139:909-919. http://dx.doi.org/10.1378/chest.10-0166.
3. Sun HY, Fujitani S, Quintiliani R, Yu VL. 2011. Pneumonia due to Pseudomonas aeruginosa. Part II. Antimicrobial resistance, pharmacodynamic concepts, and antibiotic therapy. Chest 139:1172-1185. http://dx.doi.org/10. 1378/chest.10-0167.
4. Wolter DJ, Lister PD. 2013. Mechanisms of beta-lactam resistance among Pseudomonas aeruginosa. Curr. Pharm. Des. 19:209-222. http://dx.doi.org/10.2174/ 138161213804070311.
5. Breilh D, Texier-Maugein J, Allaouchiche B, Saux MC, Boselli E. 2013. Carbapenems. J. Chemother. 25: 1-17. http://dx.doi.org/10.1179/1973947812Y. 0000000032.
6. McDougall DA, Morton AP, Playford EG. 2013. Association of ertapenem and antipseudomonal carbapenem usage and carbapenem resistance in Pseudomonas aeruginosa among 12 hospitals in Queensland, Australia. J. Antimicrob. Chemother. 68:457-460. http://dx.doi.org/10.1093/jac/dks385.
7. Alvarez-Lerma F, Grau S. 2012. Management of antimicrobial use in the intensive care unit. Drugs 72: 447-470. http://dx.doi.org/10.2165/11599520- 000000000-00000.
8. Jones RN, Huynh HK, Biedenbach DJ. 2004. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob. Agents Chemother. 48: 3136-3140. http://dx.doi.org/10.1128/AAC.48.8.3136-3140.2004. (Pubitemid 38989188)
9. Jones RN, Sader HS, Fritsche TR. 2005. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn. Microbiol. Infect. Dis. 52: 71-74. http://dx.doi.org/10.1016/j.diagmicrobio.2004.12.008. (Pubitemid 40692744)
10. Sakyo S, Tomita H, Tanimoto K, Fujimoto S, Ike Y. 2006. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. J. Antibiot. (Tokyo) 59:220-228. http://dx.doi.org/10.1038/ja.2006.31. (Pubitemid 43854733)
11. Mushtaq S, Ge Y, Livermore DM. 2004. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob. Agents Chemother. 48:3086-3092. http://dx.doi.org/10.1128/AAC.48.8.3086-3092.2004. (Pubitemid 38989178)
12. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. 2008. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit. Care Med. 36:1089-1096. http://dx.doi.org/10.1097/CCM.0b013e3181691b99. (Pubitemid 351482655)
13. Kollef MH, Chastre J, Clavel M, Restrepo MI, Michiels B, Kaniga K, Cirillo I, Kimko H, Redman R. 2012. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit. Care 16:R218. http://dx.doi.org/10.1186/cc11862.
14. Rouby JJ, Martin De Lassale E, Poete P, Nicolas MH, Bodin L, Jarlier V, Le Charpentier Y, Grosset J, Viars P. 1992. Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects. Am. Rev. Respir. Dis. 146:1059-1066. http://dx.doi.org/10.1164/ajrccm/146.4.1059.
15. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18: 268-281. http://dx.doi.org/10.1111/j. 1469-0691.2011.03570.x.
16. Ratkai C, Peixe LV, Grosso F, Freitas AR, Antunes P, Fodor E, Hajdu E, Nagy E. 2010. Successful application of the DiversiLab repetitive-sequence-based PCR typing system for confirmation of the circulation of a multiresistant Pseudomonas aeruginosa clone in different hospital wards. Diagn. Microbiol. Infect. Dis. 67:202-206. http://dx.doi.org/10.1016/j.diagmicrobio.2010.01.010.
17. Doleans-Jordheim A, Cournoyer B, Bergeron E, Croize J, Salord H, Andre J, Mazoyer MA, Renaud FN, Freney J. 2009. Reliability of Pseudomonas aeruginosa semi-automated rep-PCR genotyping in various epidemiological situations. Eur. J. Clin. Microbiol. Infect. Dis. 28:1105-1111. http://dx.doi.org/10.1007/s10096- 009-0755-z.
18. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. 2002. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 122:262-268. http://dx.doi.org/10.1378/ chest.122.1.262. (Pubitemid 34754172)
19. McCabe WR, Jackson GG. 1982. Gram-negative bacteremia. Arch. Intern. Med. 110:2957-2963.
20. Le Gall JR, Lemeshow S, Saulnier F. 1993. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957-2963. http://dx.doi.org/10.1001/jama.270.24.2957. (Pubitemid 24000804)
21. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H. 1996. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 22:707-710.
22. Weinberg PF, Matthay MA, Webster RO, Roskos KV, Goldstein IM, Murray JF. 1984. Biologically active products of complement and acute lung injury in patients with the sepsis syndrome. Am. Rev. Respir. Dis. 130:791-796. (Pubitemid 15209562)
23. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. 2012. Acute respiratory distress syndrome: the Berlin definition. JAMA 307:2526-2533. http://dx.doi.org/10.1001/jama.2012.5669.
24. Luyt CE, Chastre J, Fagon JY. 2004. Value of the clinical pulmonary infection score for the identification and management of ventilator-associated pneumonia. Intensive Care Med. 30:844-852. http://dx.doi.org/10.1007/s00134-003- 2125-0. (Pubitemid 38639476)
25. Nordmann P, Picazo JJ, Mutters R, Korten V, Quintana A, Laeuffer JM, Seak JC, Flamm RK, Morrissey I. 2011. Comparative activity of carbapenem testing: the COMPACT study. J. Antimicrob. Chemother. 66:1070-1078. http://dx.doi.org/10. 1093/jac/dkr056.
26. Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, Kim M. 2010. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect. Control Hosp. Epidemiol. 31:47-53. http://dx.doi.org/10.1086/649021.
27. Giantsou E, Manolas K. 2011. Superinfections in Pseudomonas aeruginosa ventilator-associated pneumonia. Minerva Anestesiol. 77: 964 -970.
28. Francois B, Luyt CE, Dugard A, Wolff M, Diehl JL, Jaber S, Forel JM, Garot D, Kipnis E, Mebazaa A, Misset B, Andremont A, Ploy MC, Jacobs A, Yarranton G, Pearce T, Fagon JY, Chastre J. 2012. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Crit. Care Med. 40:2320-2326. http://dx.doi.org/10. 1097/CCM.0b013e31825334f6.
29. Combes A, Figliolini C, Trouillet JL, Kassis N, Dombret MC, Wolff M, Gibert C, Chastre J. 2003. Factors predicting ventilator-associated pneumonia recurrence. Crit. Care Med. 31:1102-1107. http://dx.doi.org/10.1097/01.CCM. 0000059313.31477.2C. (Pubitemid 36444420)
30. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S. 2003. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290:2588-2598. http://dx.doi.org/10.1001/jama. 290.19.2588. (Pubitemid 37443289)
31. Heyland DK, Dodek P, Muscedere J, Day A, Cook D. 2008. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit. Care Med. 36:737-744. http://dx.doi.org/10.1097/01.CCM.0B013E31816203D6.
32. Brunkhorst FM, Oppert M, Marx G, Bloos F, Ludewig K, Putensen C, Nierhaus A, Jaschinski U, Meier-Hellmann A, Weyland A, Grundling M, Moerer O, Riessen R, Seibel A, Ragaller M, Buchler MW, John S, Bach F, Spies C, Reill L, Fritz H, Kiehntopf M, Kuhnt E, Bogatsch H, Engel C, Loeffler M, Kollef MH, Reinhart K, Welte T. 2012. Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA 307:2390-2399. http://dx.doi.org/10.1001/jama.2012.5833.
33. Planquette B, Timsit JF, Misset B, Schwebel C, Azoulay E, Adrie C, Vesin A, Jamali S, Zahar JR, Allaouchiche B, Souweine B, Darmon M, Dumenil AS, Goldgran-Toledano D, Mourvillier B, Bedos JP. 2013. Pseudomonas aeruginosa ventilator-associated pneumonia: predictive factors of treatment failure. Am. J. Respir. Crit. Care Med. 188:69-76. http://dx.doi.org/10.1164/rccm.201210- 1897OC.